Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3) which is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth. MW: 150 KD.